Surgery and radiotherapy are the standard treatment options for patients with squamous cell
carcinoma of the head and neck (SCCHN). Chemotherapy and chemoradiotherapy are new …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Introduction The purpose of this study was to evaluate the clinical efficacy in our daily
practice, outside clinical trials, of cetuximab plus radiotherapy in a majority of treatment …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …

Head and neck cancer is the sixth most common cancer worldwide. At present, globally
about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are …

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor
receptor. The role of cetuximab is paramount in several subsets of head and neck cancer. In …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

The majority of the head and neck cancers are squamous cell carcinomas, which commonly
overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal antibody that …